

Special Issue

Recent Scientific Advances in Vaccine Platforms

Message from the Guest Editors

Vaccines are recognized as the most cost-effective means of preventing the spread of infectious diseases. However, the constant evolution of pathogens and the emergence of new infectious agents pose significant challenges to vaccine development. Due to the emergence of innovative vaccine platforms, vaccine development has made significant progress in recent years. This Special Issue of the journal *Vaccines* aims to showcase recent breakthroughs in vaccine platforms. This collection will include articles exploring various vaccine platforms, such as mRNA-based vaccines, viral vector vaccines, nanomaterial vaccines, antigen delivery systems, novel adjuvants, etc. Key areas of focus will include the latest discoveries in the development of novel vaccine platforms, the optimization of current vaccine platforms and exploration of their mechanisms, and the application of vaccine platforms to improve vaccine efficacy and safety. Articles that explore the platforms' roles at all stages of vaccine development, such as antigen identification, vaccine formulation, vaccine production, and vaccination, are welcome for submission.

Guest Editors

Prof. Dr. Pan Tao

College of Veterinary Medicine, Huazhong Agricultural University,
Wuhan, China

Dr. Jingen Zhu

Department of Biology, Catholic University of America, Washington, DC,
USA

Deadline for manuscript submissions

closed (30 September 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/181828

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).